RESUMO
Understanding the proportion of SARS-CoV-2 patients with Mycoplasmapneumoniae coinfection is crucial for treating patients suffering from coronavirus disease (COVID-19), help to ensure responsible use of antibiotics and minimize the negative consequences of overuse. In addition, this knowledge could have an impact on empirical antibiotic management guidelines for patients with COVID-19. This systematic review aimed to identify the prevalence of M. pneumoniae in patients with coronavirus disease 2019 (COVID-19). A bibliographic search of studies published in Spanish or English was conducted using the PubMed search engine. Fourteen articles from different continents (America, Asia and Europe) were included, involving a total of 5855 patients in these studies. The mean age of COVID-19 patients with M. pneumoniae was 48 years old (range 1-107), most of whom were male. The detection of laboratory-confirmed M. pneumoniae infection varied between 0 and 33.3%. Most of patients referred fever, cough, and dyspnea, and received empirical antibiotic treatment. Bacterial coinfection was not associated with increased ICU admission and mortality. The prevalence of coinfection showed extremely dissimilar figures according to the population studied and diagnostic criteria. However, it is important to develop Latin American studies, given the heterogeneity observed in the studies conducted in different countries. Standardized definitions should be developed in order to be able to assess the impact of coinfections in patients with a diagnosis of COVID-19.
Assuntos
COVID-19 , Coinfecção , Pneumonia por Mycoplasma , Humanos , COVID-19/complicações , COVID-19/epidemiologia , Coinfecção/epidemiologia , Pneumonia por Mycoplasma/epidemiologia , Pneumonia por Mycoplasma/complicações , Pneumonia por Mycoplasma/tratamento farmacológico , Prevalência , Mycoplasma pneumoniae , Criança , Idoso , Adulto , Idoso de 80 Anos ou mais , Pré-Escolar , Adulto Jovem , Pessoa de Meia-Idade , Adolescente , Masculino , Antibacterianos/uso terapêutico , Lactente , FemininoRESUMO
OBJECTIVE: Early diagnosis of Severity Mycoplasma Pneumoniae Pneumonia (SMPP) has been a worldwide concern in clinical practice. Two cytokines, soluble Triggering Receptor Expressed on Myeloid cells (sTREM-1) and Interferon-Inducible Protein-10 (IP-10), were proved to be implicated in bacterial infection diseases. However, the diagnostic value of sTREM-1 and IP-10 in MPP was poorly known. This study aimed to investigate the diagnostic value of sTREM-1 and IP-10 for SMPP. METHODS: In this prospective study, the authors enrolled 44 children with MPP, along with their clinical information. Blood samples were collected, and cytokine levels of sTREM-1 and IP-10 were detected with ELISA assay. RESULTS: Serum levels of sTREM-1 and IP-10 were positively correlated with the severity of MPP. In addition, sTREM-1 and IP-10 have significant potential in the diagnosis of SMPP with an Area Under Curve (AUC) of 0.8564 (p-value = 0.0001, 95% CI 0.7461 to 0.9668) and 0.8086 (p-value = 0.0002, 95% CI 0.6918 to 0.9254) respectively. Notably, the combined diagnostic value of sTREM-1 and IP-10 is up to 0.911 in children with SMPP (p-value < 0.001, 95% CI 0.830 to 0.993). CONCLUSIONS: Serum cytokine levels of sTREM-1 and IP-10 have a great potential diagnostic value in children with SMPP.
Assuntos
Biomarcadores , Quimiocina CXCL10 , Ensaio de Imunoadsorção Enzimática , Pneumonia por Mycoplasma , Receptores Imunológicos , Índice de Gravidade de Doença , Receptor Gatilho 1 Expresso em Células Mieloides , Humanos , Receptor Gatilho 1 Expresso em Células Mieloides/sangue , Feminino , Masculino , Pneumonia por Mycoplasma/diagnóstico , Pneumonia por Mycoplasma/sangue , Criança , Estudos Prospectivos , Pré-Escolar , Quimiocina CXCL10/sangue , Receptores Imunológicos/sangue , Biomarcadores/sangue , Glicoproteínas de Membrana/sangue , Mycoplasma pneumoniae , Lactente , Sensibilidade e Especificidade , Curva ROC , AdolescenteRESUMO
OBJECTIVE: This study aimed to investigate the clinical significance of serum microRNA-146a and pro-inflammatory factors in children with Mycoplasma pneumoniae pneumonia after azithromycin treatment. microRNA-146a is known to regulate inflammatory responses, and excessive inflammation is a primary characteristic of MPP. METHODS: Children with MPP received conventional symptomatic therapy along with intravenous administration of azithromycin for one week. Serum levels of microRNA-146a and pro-inflammatory factors were measured using RT-qPCR and ELISA kits, respectively. The correlation between microRNA-146a and pro-inflammatory factors was analyzed by the Pearson method. Pulmonary function indexes were assessed using a pulmonary function analyzer, and their correlation with microRNA-146a and pro-inflammatory factors after treatment was evaluated. Children with MPP were divided into effective and ineffective treatment groups, and the clinical significance of microRNA-146a and pro-inflammatory factors was evaluated using receiver operating characteristic curves and logistic multivariate regression analysis. RESULTS: Serum microRNA-146a was downregulated in children with MPP but upregulated after azithromycin treatment, contrasting with the trend observed for pro-inflammatory factors. MicroRNA-146a showed a negative correlation with pro-inflammatory cytokines. Pulmonary function parameters were initially reduced in children with MPP, but increased after treatment, showing positive/inverse associations with microRNA-146a and pro-inflammatory factors. Higher microRNA-146a and lower pro-inflammatory factors predicted better efficacy of azithromycin treatment. MicroRNA-146a, tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), interleukin-8 (IL-8), and forced expiratory volume in the first second/forced vital capacity (FEV1/FVC) were identified as independent factors influencing treatment efficacy. CONCLUSION: Azithromycin treatment in children with MPP upregulates microRNA-146a, downregulates pro-inflammatory factors, and effectively improves pulmonary function.
Assuntos
MicroRNAs , Pneumonia por Mycoplasma , Criança , Humanos , Azitromicina/uso terapêutico , Mycoplasma pneumoniae , Relevância Clínica , Pneumonia por Mycoplasma/tratamento farmacológico , MicroRNAs/uso terapêuticoRESUMO
Abstract Objective This study aimed to investigate the clinical significance of serum microRNA-146a and pro-inflammatory factors in children with Mycoplasma pneumoniae pneumonia after azithromycin treatment. microRNA-146a is known to regulate inflammatory responses, and excessive inflammation is a primary characteristic of MPP. Methods Children with MPP received conventional symptomatic therapy along with intravenous administration of azithromycin for one week. Serum levels of microRNA-146a and pro-inflammatory factors were measured using RT-qPCR and ELISA kits, respectively. The correlation between microRNA-146a and pro-inflammatory factors was analyzed by the Pearson method. Pulmonary function indexes were assessed using a pulmonary function analyzer, and their correlation with microRNA-146a and pro-inflammatory factors after treatment was evaluated. Children with MPP were divided into effective and ineffective treatment groups, and the clinical significance of microRNA-146a and pro-inflammatory factors was evaluated using receiver operating characteristic curves and logistic multivariate regression analysis. Results Serum microRNA-146a was downregulated in children with MPP but upregulated after azithromycin treatment, contrasting with the trend observed for pro-inflammatory factors. MicroRNA-146a showed a negative correlation with pro-inflammatory cytokines. Pulmonary function parameters were initially reduced in children with MPP, but increased after treatment, showing positive/inverse associations with microRNA-146a and pro-inflammatory factors. Higher microRNA-146a and lower pro-inflammatory factors predicted better efficacy of azithromycin treatment. MicroRNA-146a, tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), interleukin-8 (IL-8), and forced expiratory volume in the first second/forced vital capacity (FEV1/FVC) were identified as independent factors influencing treatment efficacy. Conclusion Azithromycin treatment in children with MPP upregulates microRNA-146a, downregulates pro-inflammatory factors, and effectively improves pulmonary function.
RESUMO
Abstract Objective Early diagnosis of Severity Mycoplasma Pneumoniae Pneumonia (SMPP) has been a worldwide concern in clinical practice. Two cytokines, soluble Triggering Receptor Expressed on Myeloid cells (sTREM-1) and Interferon-Inducible Protein-10 (IP-10), were proved to be implicated in bacterial infection diseases. However, the diagnostic value of sTREM-1 and IP-10 in MPP was poorly known. This study aimed to investigate the diagnostic value of sTREM-1 and IP-10 for SMPP. Methods In this prospective study, the authors enrolled 44 children with MPP, along with their clinical information. Blood samples were collected, and cytokine levels of sTREM-1 and IP-10 were detected with ELISA assay. Results Serum levels of sTREM-1 and IP-10 were positively correlated with the severity of MPP. In addition, sTREM-1 and IP-10 have significant potential in the diagnosis of SMPP with an Area Under Curve (AUC) of 0.8564 (p-value = 0.0001, 95% CI 0.7461 to 0.9668) and 0.8086 (p-value = 0.0002, 95% CI 0.6918 to 0.9254) respectively. Notably, the combined diagnostic value of sTREM-1 and IP-10 is up to 0.911 in children with SMPP (p-value < 0.001, 95% CI 0.830 to 0.993). Conclusions Serum cytokine levels of sTREM-1 and IP-10 have a great potential diagnostic value in children with SMPP.
RESUMO
Introduction: It is currently reported that Mycoplasma pneumoniae (MP) infection can occur at a young age. Objective: Describe the findings of the molecular detection of MP in respiratory secretions of patients who required hospitalization due to acute respiratory infection, in a pediatric hospital. Population and methods: Data collection was performed by reviewing medical records and statistical correlation using the chi-square test. 919 patients from one month to fourteen years and eleven months of age who required hospitalization for acute respiratory infection were included. The frequency by age and sex of the isolation of MP was analyzed together with other respiratory pathogens. Results: Mycoplasma pneumoniae was the most frequently detected microorganism (30%), followed by respiratory syncytial virus (RSV) (25.1%). Age and sex did not behave as a predictor of detection for MP. In 47.3% of the patients, MP was isolated together with another pathogen, the most prevalent was RSV 31.3%. Regarding the diagnoses at discharge of the group of patients with isolation of MP and a another microorganism, 50.8% had bronchiolitis, and in the group of patients with identification only of MP this percentage was 32.4%. The difference in the distributions was statistically significant (p <0.05). Conclusion: We conclude that Mycoplasma pneumoniae detection is frequent in our environment and occurs in a significant number of cases together with another respiratory pathogen. These findings should prompt further study to determine their clinical relevance.
Introducción: Actualmente se encuentra reportado que la infección por Mycoplasma pneumoniae (MP) puede darse en edades tempranas de la vida. Objetivo: Describir los hallazgos de la detección molecular de MP en secreciones respiratorias de pacientes que requirieron internación por infección respiratoria aguda, en un hospital pediátrico. Población y métodos: La recolección de datos se realizó mediante revisión de historias clínicas y la correlación estadística mediante test de chi-cuadrado. Se incluyeron 919 pacientes de un mes a catorce años y once meses de edad que requirieron internación por infección respiratoria aguda. Se analizó frecuencia por edad y sexo del asilamiento de MP conjuntamente con otros patógenos respiratorios. Resultados: MP fue el microorganismo más frecuentemente detectado (30 %), seguido del Virus Respiratorio Sincitial (VRS) (25.1 %). La edad y el sexo no se comportaron como predictor de la detección para MP. En un 47.3 % de los pacientes se aisló MP conjuntamente con otro patógeno, el más prevalente fue el VRS 31.3 %. En cuanto a los diagnósticos al egreso del grupo de pacientes con aislamiento de MP más otro microorganismo, el 50.8 % presentaron bronquiolitis, y en el grupo de pacientes con identificación solo de MP este porcentaje fue de 32.4 %. La diferencia de las distribuciones fue estadísticamente significativa (p<0.05). Conclusión: Concluimos que la detección MP es frecuente en nuestro medio y se presenta en un número importante de casos conjuntamente con otro patógeno respiratorio. Estos hallazgos deberían impulsar a continuar el estudio para determinar la relevancia clínica de los mismos.
Assuntos
Criança Hospitalizada , Mycoplasma pneumoniae , Criança , Humanos , Estudos RetrospectivosRESUMO
Abstract Objective: This study aimed to evaluate the role of miRNA-492 in the progression of mycoplasma pneumoniae (MP) infection in pediatric patients. Methods: Forty-six children admitted to the present study's hospital and diagnosed with mycoplasma pneumonia were recruited as the study group from March 2018 to August 2019, and 40 healthy children were selected as the control group. Results: The expression levels of miRNA-492, TNF-α, IL-6 and IL-18 in the study group were significantly higher than those in the control group (p < 0.05). There was no significant correlation between miRNA-492 and most of the immune-correlated indicators in the study group, except for IL-6, IL-18 and HMGB1. Meanwhile, overexpression of miRNA-492 increased IL-6 secretion in PMA-activated monocytes (p < 0.01). Conclusion: The present study's results suggested that miRNA-492 might play a role in the pathogenesis of mycoplasma pneumoniae pneumonia in children by regulating the secretion of immune-inflammatory factors such as IL-6 and IL-18 in the mononuclear macrophages.
RESUMO
OBJECTIVE: This study aimed to evaluate the role of miRNA-492 in the progression of mycoplasma pneumoniae (MP) infection in pediatric patients. METHODS: Forty-six children admitted to the present study's hospital and diagnosed with mycoplasma pneumonia were recruited as the study group from March 2018 to August 2019, and 40 healthy children were selected as the control group. RESULTS: The expression levels of miRNA-492, TNF-α, IL-6 and IL-18 in the study group were significantly higher than those in the control group (p < 0.05). There was no significant correlation between miRNA-492 and most of the immune-correlated indicators in the study group, except for IL-6, IL-18 and HMGB1. Meanwhile, overexpression of miRNA-492 increased IL-6 secretion in PMA-activated monocytes (p < 0.01). CONCLUSION: The present study's results suggested that miRNA-492 might play a role in the pathogenesis of mycoplasma pneumoniae pneumonia in children by regulating the secretion of immune-inflammatory factors such as IL-6 and IL-18 in the mononuclear macrophages.
Assuntos
MicroRNAs , Pneumonia por Mycoplasma , Criança , Humanos , Pneumonia por Mycoplasma/diagnóstico , Interleucina-18 , Mycoplasma pneumoniae/genética , Interleucina-6RESUMO
Introducción: Mycoplasma pneumoniae es causa frecuente de infecciones respiratorias en niños y jóvenes. Los macrólidos son la primera línea de tratamiento. La rápida emergencia de resistencia a estos antimicrobianos ha motivado el desarrollo de métodos moleculares para su detección en muestras clínicas positivas a este patógeno. Objetivo: Implementar un método de reacción en cadena de la polimerasa en tiempo real (RT-PCR) para la detección de resistencia a macrólidos a partir de muestras clínicas positivas a M. pneumoniae. Métodos: Se implementó una RT-PCR para la detección de las mutaciones A2058G y A2059G en el ARNr 23S de M. pneumoniae. Se analizaron 24 muestras clínicas positivas a M. pneumoniae, que provenían de pacientes con síntomas respiratorios. Se evaluó la sensibilidad, especificidad, repetibilidad y reproducibilidad de la RT-PCR. Resultados: La RT-PCR mostró un 100 % de especificidad para M. pneumoniae y un 92 % de sensibilidad, con un límite de detección de 2 copias/µL, que equivale a 10 copias/reacción. Además, se demostró la reproducibilidad y repetibilidad de estos resultados. Se obtuvo una correcta identificación de los genotipos salvaje y mutante, correspondientes a cada control. De las muestras clínicas positivas a M. pneumoniae, el 77,3 % (17/22) se identificó como sensible a macrólidos y el 22,7 % (5/22) como resistente. Conclusiones: La alta sensibilidad y especificidad del método de RT-PCR implementado permite que el Laboratorio Nacional de Referencia de Micoplasmas del Instituto de Medicina Tropical Pedro Kourí cuente con un método eficaz para el diagnóstico de M. pneumoniae resistente a macrólidos.
Introduction: Mycoplasma pneumoniae is a common cause of respiratory track infections in children and young adults. Macrolides are the first-line treatment. The rapid emergence of resistance to these antimicrobials has motivated the development of molecular methods for their detection in clinical samples positive for this pathogen. Objective: To implement a real-time polymerase chain reaction (RT-PCR) method for the detection of macrolide resistance in M. pneumoniae positive clinical samples. Methods: An RT-PCR was implemented to detect mutations A2058G and A2059G in 23S rRNA of M. pneumoniae. M. pneumoniae positive clinical samples from 24 patients with respiratory symptoms were analyzed. Sensitivity, specificity, repeatability and reproducibility of the RT-PCR assays were evaluated. Results: The RT-PCR assays showed 100% specificity to M. pneumoniae, and 92% sensitivity with a detection limit of 2 copies/µL, equivalent to 10 copies/reaction. Moreover, the repeatability and reproducibility of these results were demonstrated. Wild and mutant genotypes associated to each control were properly identified. Of the clinical samples positive for M. pneumoniae, 77.3% (17/22) were macrolide-sensitive and 22.7% (5/22) were macrolide-resistant. Conclusions: The high sensitivity and specificity of the RT-PCR method implemented provides the National Reference Laboratory of Mycoplasmas of the Institute of Tropical Medicine Pedro Kourí with an effective method for the diagnosis of macrolide-resistant M. pneumoniae.
Assuntos
HumanosRESUMO
Pneumonia is a serious global health problem that accounts for over one million deaths annually. Among the main microorganisms causing pneumonia, Mycoplasma pneumoniae is one of the most common ones for which a vaccine is immediately required. In this context, a multi-epitope vaccine against this pathogen could be the best option that can induce effective immune response avoiding any serious adverse reactions. In this study, using an immunoinformatics approach we have designed a multi-epitope vaccine (mpme-VAC/STV-1) against M. pneumoniae. Our designed mpme-VAC/STV-1 is constructed using CTL (cytotoxic T lymphocyte), HTL (Helper T lymphocyte), and B-cell epitopes. These epitopes are selected from the core proteins of 88 M. pneumoniae genomes that were previously identified through reverse vaccinology approaches. The epitopes were filtered according to their immunogenicity, population coverage, and several other criteria. Sixteen CTL/B- and thirteen HTL/B- epitopes that belong to 5 core proteins were combined together through peptide linkers to develop the mpme-VAC/STV-1. The heat-labile enterotoxin from E. coli was used as an adjuvant. The designed mpme-VAC/STV-1 is predicted to be stable, non-toxic, non-allergenic, non-host homologous, and with required antigenic and immunogenic properties. Docking and molecular dynamic simulation of mpme-VAC/STV-1 shows that it can stimulate TLR2 pathway mediated immunogenic reactions. In silico cloning of mpme-VAC/STV-1 in an expression vector also shows positive results. Finally, the mpme-VAC/STV-1 also shows promising efficacy in immune simulation tests. Therefore, our constructed mpme-VAC/STV-1 could be a safe and effective multi-epitope vaccine for immunization against pneumonia. However, it requires further experimental and clinical validations.
Assuntos
Epitopos de Linfócito T , Mycoplasma pneumoniae , Biologia Computacional/métodos , Epitopos de Linfócito T/química , Escherichia coli , Simulação de Acoplamento Molecular , Simulação de Dinâmica Molecular , Mycoplasma pneumoniae/genética , Vacinas de Subunidades Antigênicas/químicaRESUMO
Microbial communities are considered decisive for maintaining a healthy situation or for determining diseases. Acute myocardial infarction (AMI) is an important complication of atherosclerosis caused by the rupture of atheroma plaques containing proinflammatory cytokines, reactive oxygen species, oxidized low-density lipoproteins (oxLDL), damaged proteins, lipids, and DNA, a microenvironment compatible with a pathogenic microbial community. Previously, we found that archaeal DNA-positive infectious microvesicles (iMVs) were detected in vulnerable plaques and in the sera of Chagas disease patients with heart failure. Now, we characterize and quantify the levels of serum microbiome extracellular vesicles through their size and content using morphomolecular techniques to differentiate clinical outcomes in coronary artery disease (CAD). We detected increased numbers of large iMVs (0.8-1.34 nm) with highly negative surface charge that were positive for archaeal DNA, Mycoplasma pneumoniae antigens and MMP9 in the sera of severe AMI patients, strongly favoring our hypothesis that pathogenic archaea may play a role in the worst outcomes of atherosclerosis. The highest numbers of EVs <100 nm (exosomes) and MVs from 100 to 200 nm in the stable atherosclerotic and control healthy groups compared with the AMI groups were indicative that these EVs are protective, entrapping and degrading infectious antigens and active MMP9 and protect against the development of plaque rupture. Conclusion: A microbiome with pathogenic archaea is associated with high numbers of serum iMVs in AMI with the worst prognosis. This pioneering work demonstrates that the morphomolecular characterization and quantification of iEVs in serum may constitute a promising serum prognostic biomarker in CAD.
RESUMO
We used multi-locus variable-number of tandem repeat analysis (MLVA), p1, multi-locus sequence (MLS) and single nucleotide polymorphisms (SNP) typing to characterize a collection of Mycoplasma pneumoniae strains from Cuba and Germany. Among 67 strains, 5 p1, 7 MLVA, 11 MLS, and 11 SNP types were obtained.
Assuntos
Técnicas de Tipagem Bacteriana/métodos , Tipagem de Sequências Multilocus/métodos , Mycoplasma pneumoniae/isolamento & purificação , Pneumonia por Mycoplasma/microbiologia , Cuba , Genótipo , Alemanha , Humanos , Repetições Minissatélites , Mycoplasma pneumoniae/classificação , Mycoplasma pneumoniae/genética , Polimorfismo de Nucleotídeo ÚnicoRESUMO
M. pneumoniae es un agente etiológico importante para neumonía atípica en niños. Por sus características inmunogénicas, la presentación clínica no alcanza una certeza diagnóstica. Métodos comunes usados para cuadros de etiología diferente, no producen en este caso hallazgos facilitadores del diagnóstico que generen decisiones terapéuticas apropiadas. El objetivo de esta revisión es describir la utilidad del uso de la PCR y serología IgM para M. pneumoniae en niños, conociendo que son las técnicas más usadas. Método: Con la estrategia Pico se buscó material científico en bases de datos Pubmed, Embase, Chrocane; verificando términos Mesh y Decs. Criterios de exclusión: abstracts, otros microorganismos, población adulta, pruebas de laboratorio diferentes, reportes de caso y cartas al editor. Es importante detectar M. pneumoniae por la aparición de cepas resistentes al tratamiento con macrólidos; secundario a no tener pruebas confiables. La serología, no es altamente sensible en etapas iniciales; pero, mediante pruebas pareadas se confirma el diagnóstico. Para agilizar la detección proponen la PCR; dependiendo de ciertas condiciones, podría hacerse diagnóstico. Si no se logran los requerimientos necesarios, el uso de los dos test resulta confiable. En conclusión, No hay superioridad de un test específico; algunos autores sugieren las dos pruebas para un diagnóstico rápido y evitar la resistencia por uso indiscriminado de antibióticos
M. pneumoniae is an important etiologic agent for atypical pneumonia in children. Due to its immunogenic characteristics, the clinical signs do not reach diagnostic certainty. Common methods used for different etiology do not produce diagnostic facilitating findings for therapeutic decisions. The objective of this review is to describe the usefulness of PCR and IgM serology for M. pneumoniae in children, considering that these are the most used techniques. Making use of the Pico strategy, scientific material was searched in PubMed, Embase, Chrocane databases; verifying terms Mesh and Decs. Exclusion criteria: abstracts, other microorganisms, adult population, different laboratory tests, case reports and letters to the editor. It is important to detect M. pneumoniae by the appearance of resistant to macrolide treatment microorganisms; secondary to not having reliable labs. Serology is not highly sensitive, in early stages; but, with paired tests, it confirms the diagnosis. To expedite detection, some propose PCR; depending on certain conditions, it could make a diagnosis. If the necessary requirements are not achieved, the use of the two tests is reliable. In conclusion, there is no superiority of a specific test; some studies suggest both tests for a rapid diagnosis and avoid resistance by indiscriminate use of antibiotics
RESUMO
M. pneumoniae es un agente etiológico importante para neumonía atípica en niños. Por sus características inmunogénicas, la presentación clínica no alcanza una certeza diagnóstica. Métodos comunes usados para cuadros de etiología diferente, no producen en este caso hallazgos facilitadores del diagnóstico que generen decisiones terapéuticas apropiadas. El objetivo de esta revisión es describir la utilidad del uso de la PCR y serología IgM para M. pneumoniae en niños, conociendo que son las técnicas más usadas. Método: Con la estrategia Pico se buscó material científico en bases de datos Pubmed, Embase, Chrocane; verificando términos Mesh y Decs. Criterios de exclusión: abstracts, otros microorganismos, población adulta, pruebas de laboratorio diferentes, reportes de caso y cartas al editor. Es importante detectar M. pneumoniae por la aparición de cepas resistentes al tratamiento con macrólidos; secundario a no tener pruebas confiables. La serología, no es altamente sensible en etapas iniciales; pero, mediante pruebas pareadas se confirma el diagnóstico. Para agilizar la detección proponen la PCR; dependiendo de ciertas condiciones, podría hacerse diagnóstico. Si no se logran los requerimientos necesarios, el uso de los dos test resulta confiable. En conclusión, No hay superioridad de un test específico; algunos autores sugieren las dos pruebas para un diagnóstico rápido y evitar la resistencia por uso indiscriminado de antibióticos
M. pneumoniae is an important etiologic agent for atypical pneumonia in children. Due to its immunogenic characteristics, the clinical signs do not reach diagnostic certainty. Common methods used for different etiology do not produce diagnostic facilitating findings for therapeutic decisions. The objective of this review is to describe the usefulness of PCR and IgM serology for M. pneumoniae in children, considering that these are the most used techniques. Making use of the Pico strategy, scientific material was searched in PubMed, Embase, Chrocane databases; verifying terms Mesh and Decs. Exclusion criteria: abstracts, other microorganisms, adult population, different laboratory tests, case reports and letters to the editor. It is important to detect M. pneumoniae by the appearance of resistant to macrolide treatment microorganisms; secondary to not having reliable labs. Serology is not highly sensitive, in early stages; but, with paired tests, it confirms the diagnosis. To expedite detection, some propose PCR; depending on certain conditions, it could make a diagnosis. If the necessary requirements are not achieved, the use of the two tests is reliable. In conclusion, there is no superiority of a specific test; some studies suggest both tests for a rapid diagnosis and avoid resistance by indiscriminate use of antibiotics
RESUMO
Resumen: Introducción: La infección por Mycoplasma pneumoniae (Mypn) podría estar ocurriendo a edades más tempranas, debido a fenómenos sociales como concurrencia a centros de cuidado diurno en forma más frecuente y precoz. Objetivo: estimar la prevalencia de anticuerpos anti-Mypn en niños de 0-12 años, y explorar si la edad, asistencia a centro de cuidados diurnos/escuela, hacinamiento o convivencia con niños incrementan el riesgo de seropositividad. Pacientes y Método: Estudio transversal incluyendo niños de 0-12 años de edad que requirieron extracciones de sangre para control, por lo demás sanos. En todos los casos se consignaron las variables mencionadas y se determinó IgG anti-Mypn mediante enzimoinmunoanálisis. Se evaluó la asociación entre predictores y seropositividad en un modelo de regresión logística. Resultados: Se incluyeron 232 pacientes (edad promedio 56,4 ± 40,0 meses). El 56,9% concurría a centro de cuidado diurno/escuela, 63,8% convivían con menores de 12 años y 15,9% presentaban hacinamiento. El 14,6% presentaba anticuerpos anti-Mypn. Los niños seroposi- tivos no mostraron diferencias significativas con aquellos seronegativos en relación a edad (63,1 ± 40,7 vs. 55,4 ± 41,3 meses), escolaridad (64,7% vs 55,5%), hacinamiento (14,7% vs 14,9%), ni con vivencia con menores (64,7% vs 63,6%). La edad tampoco se mostró como predictor independiente de seropositividad en el modelo multivariado. Conclusión: La prevalencia de anticuerpos anti-Mypn fue 14,6%. La edad no fue predictor de seropositividad.
Abstract: Introduction: Mycoplasma pneumoniae (Mypn) infection could be occurring at an earlier age due to social pheno mena such as attending daycare centers more frequently and earlier than decades ago. Objective: to estimate the prevalence of anti-Mypn antibodies in children aged 0-12 years, and to explore whether age, attendance to daycare center/school, overcrowding or the presence of children aged below 12 years in the households increase the risk of seropositivity. Patients and Method: Cross-sectional stu dy including healthy children aged 0-12 years which required blood draws for routine laboratory tests. In all cases, the aforementioned variables were recorded and anti-Mypn IgG was determined by enzyme immunoassay. The association between predictors and seropositivity was assessed in a logistic regression model. Results: We included 232 patients (average age 56.4 ± 40.0 months). 56.9% attended a daycare center/school, 63.8% co-habited with children under 12 years old, and 15.9% lived in overcrowded households. The prevalence of anti-Mypn antibodies was 14.6%. There were no significant differences between seropositive and seronegative children regarding age (63.1 ± 40.7 vs. 55.4 ± 41.3 months), school/day-care attendance (64.7% vs. 55.5%), overcrowding (14.7% vs. 14.9%), or co-habiting with children (64.7% vs. 63.6%). Age was not an independent predictor of seropositivity in the multivariate model. Conclusion: The prevalence of anti-Mypn antibodies in children was 14.6% and age was not a predictor of seropositivity.
Assuntos
Humanos , Masculino , Feminino , Recém-Nascido , Lactente , Pré-Escolar , Criança , Pneumonia por Mycoplasma/epidemiologia , Anticorpos Antibacterianos/sangue , Mycoplasma pneumoniae/imunologia , Argentina/epidemiologia , Pneumonia por Mycoplasma/diagnóstico , Pneumonia por Mycoplasma/sangue , Instituições Acadêmicas , Biomarcadores/sangue , Aglomeração , Modelos Logísticos , Estudos Soroepidemiológicos , Creches , Prevalência , Estudos Transversais , Fatores de RiscoRESUMO
Resumen La neumonía es una infección a nivel del parénquima pulmonar, que puede categorizarse según el lugar de contagio como adquirida en la comunidad (NAC) o nosocomial, lo cual resulta muy importante tener presente al momento de definir el manejo. Para fines del presente artículo, se hace énfasis en la NAC de etiología bacteriana, enfatizando aquellas infecciones producidas por microorganismos como: Sreptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae y Legionella sp También se hace referencia a la presentación clínica y pruebas de gabinete existentes para facilitar el diagnóstico y valorar de forma objetiva la evolución del cuadro. Se menciona la utilidad de escalas como la PSI, CURB65, SMART-COP, SCAP, entre otras, para determinar si el manejo más oportuno de la NAC es a nivel ambulatorio o intrahospitalario y, en caso de ser este último, identificar si lo más recomendado es el seguimiento en la Unidad de Cuidados Intensivos (UCI) o en salones de medicina interna. Con respecto al tratamiento, se exponen diversos esquemas de antibioticoterapia recomendados para el manejo de NAC a nivel ambulatorio, intrahospitalario y en unidad de cuidados intensivos (UCI), tales como el uso de penicilinas, inhibidores de betalactamasas, quinolonas, cefalosporinas, macrólidos, entre otros. A su vez, se mencionan los criterios que definen los tiempos de duración de los esquemas antibióticos y las recomendaciones del National Institute for Health and Care Excellence (NICE) para la educación del paciente con NAC por parte del médico tratante.
Abstract: Pneumonia is an infection located in lung parenchyma that can be classified according to the place of acquisition into Community-Acquired Pneumonia (CAP) or Hospital and Healthcare-Acquired Pneumonia, which is of major importance to define the physician management. In this article the main idea to present the bacterial CAP giving special importance to those caused by Sreptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae y Legionella sp. In addition, the following article approaches the clinical presentation and diverse laboratory tests to complement an accurate diagnosis and the evolution of the disease. The scores PSI, CURB65, SMART-COP and SCAP can be a very useful tool to help the physician determine if the patient needs to be hospitalized in an internal medicine service, intensive care unit or if the case can be handled as an outpatient. The antibiotics are keystone to treat the pneumonia, and different therapies designed to manage CAP in outpatients and inpatients are explained, such as amoxicillin, amoxixillin/clavulanate, azithromycin, cefdinir, moxifloxacin among others; as well as the criteria to determine the optimal duration of the treatment. As an addition the recommendations given by the National Institute for Health and Care Excellence (NICE) are provided to the physicians as a tool to improve patient's education and optimize the initial approach and management.
Assuntos
Humanos , Infecções Pneumocócicas/tratamento farmacológico , Pneumonia/classificação , Antibacterianos/uso terapêutico , Terapia Respiratória/tendências , Costa RicaRESUMO
Introducción: Mycoplasma penumoniae es un patógeno reconocido como principal agente causal de neumonía atípica, así como también por generar diferentes tipos de complicaciones extrapulmonares, especialmente de carácter neurológico y afectar directamente el sistema nervioso, gracias a sus mecanismos de virulencia, mimetismo y de inmunomodulación en el huésped. Causa afecciones como neuropatías, polineuropatías, encefalopatías, síndrome de Guillain Barré y otros. Objetivo: Reforzar en el área pediátrica la necesidad de modificar criterios diagnósticos e incorporar variantes clínicas del síndrome de Guillain Barre, además de instrumentos para diagnóstico de afecciones neuropáticas. Presentación del caso: Paciente masculino, 9 años 8 meses de edad, quien consulta en repetidas ocasiones por: dispepsias, episodios de diarrea, constipación y fiebre. Se constató según consulta: disbiosis, resfriado común, y finalmente, neumonía atípica por Mycoplasma Pneumoniae. Paciente evoluciona, con debilidad muscular, paresia, hiperalgesia y alodinia de extremidades superiores e inferiores. Acude a neurólogo, quien indica exámenes neurofisiológicos (velocidad de conducción nerviosa, potenciales evocados y se descartó una electromiografía, debido a la hiperalgesia). Se diagnosticó una polineuropatía axonal, la que se caracterizó por presentar ciertos aspectos del síndrome de Guillain-Barré. Tanto la evolución clínica de este síndrome, así como sus variantes clínicas, tienen un curso en adultos, caracterizado por un comienzo y signos distintos, lo que puede retrasar y errar el diagnóstico en pacientes pediátricos. Conclusiones: Hace falta nuevos criterios diagnósticos y su amplitud y herramientas de abordaje, para hacer un diagnóstico rápido y eficaz, y contribuir a la recuperación optima del paciente(AU)
Introduction: Mycoplasma pneumoniae is a pathogen know as to the main causal agent of atypical pneumonia, as well as to generate different extrapulmonary sickness, especially in neurological ways, directing to the nervous system, thanks to all its different mechanisms, like: virulence, mimetysm and immunomodulation in to the host. Producing, pathologies like neuropathies, polyneuropathies, encephalopathies, Guillain Barré Syndrome. Objetives: To highlight in the pediatric area, the need to modificate diagnosis criteria and incorporate Guillain-Barre Syndrome clinicals variants, also instruments to diagnosis of neuropathic pathologies. Case presentation: Male patient, 9 years, 8 months old, who consulted in repeated occasions for: dyspepsia, diarrhea and constipation episodes and fiber. Confirmed according to consultation: dysbiosis, common cold, and finally, atypical pneumonia by Mycoplasma Pneumoniae. The patient evolves with: muscular weakness, hyperalgesia and allodynia of upper and inferior extremities. Then, the Neurologist, indicates neurophysiological exams (nerve conduction velocity, evoked potentials, discarding an electromyography, due to hyperalgesia). Diagnosing an axonal polyneuropathy. Which was characterized to present some same aspects, from clinical course of Guillain-Barre Syndrome. Highlighting that the clinical evolution, as also, the syndrome clinical variants, has it a course in adults, characterized by a different beginning and signs, than in children. Retarding and do a wrong diagnosis in pediatric patients. Conclusion: Lack of new diagnosis criteria, the amplitude of these and tools of approach to give a fast and effective diagnosis, and contribute to the optimal recovery of the patient(AU)
Assuntos
Humanos , Masculino , Criança , Pneumonia por Mycoplasma/complicações , Pneumonia por Mycoplasma/diagnóstico , Síndrome de Guillain-Barré/complicações , Síndrome de Guillain-Barré/diagnóstico , Pneumonia por Mycoplasma/transmissãoRESUMO
Objetivo: Determinar la prevalencia de infección por gérmenes atípicos evaluada mediante la determinación de anticuerpos IgM en casos de neumonía adquirida en la comunidad en pacientes adultos inmunocompetentes atendidos en el Hospital Nacional Hipólito Unanue. Métodos: Se evaluaron a aquellos pacientes adultos inmunocompetentes que acudieron a la emergencia del Hospital Hipólito Unanue con neumonía adquirida en la comunidad entre setiembre del 2008 y enero del 2009. Se tomaron muestras de sangre para realizar serología para Mycoplasma pneumoniae y Chlamydia pneumoniae mediante la detección de niveles de inmunoglobulina M determinados por prueba de ELISA. Resultados:Se reclutaron 85 pacientes. La edad promedio fue de 65,33 ± 21,43 años. Se encontraron 3 casos de pacientes con serología positiva a IgM frente a M. pneumoniae y 1 caso positivo a C. pneumoniae. Los títulos de anticuerpos contra M. pneumoniae tuvieron una correlación altamente significativa con la edad (r=-0,28; p<0,01). se encontró una correlación estadísticamente significativa entre los índices de anticuerpos IgM frente a M. pneumoniae y C. pneumoniae (r=0,29; p<0,01). Conclusión: La infección por gérmenes atípicos no parece ser una condición frecuente en pacientes hospitalizados con diagnóstico de neumonía adquirida en la comunidad. Se deben realizar estudios en poblaciones mayores utilizando serología pareada o estudios moleculares, incluyendo pacientes ambulatorios a fin de definir el rol de patógenos atípicos en casos de neumonía a nivel nacional.
Objective: To determine the prevalence of infection due to atypical microorganisms in cases of community-acquired pneumonia in adult inmunocompetent patients seeking attention in the Hospital Nacional Hipolito Unanue. Methods: Adult inmunocompetent patients seeking medical attention in the emergency ward of Hospital Hipolito Unanue with diagnosis of community-acquired pneumonia were evaluated between september 2008 and january 2009. Blood samples were drawn for Mycoplasma pneumoniae and Chlamydia pneumoniae serology, by the detection of M Inmunoglobulin by ELISA technique. Results: We recruited 85 patients. The average age was 65.33 ± 21.43 years. We found 3 cases with positive IgM serology against M. pneumoniae and 1 case positive against C. pneumoniae. The antibody titers against M. pneumoniae had a highly significant correlation with the age (r=-0.28; p<0.01). We also found a statistically significant difference between the titers of antibodies against M. pneumoniae and those correspondent to C. pneumoniae (r=0.29; p<0.01). Conclusion: Infection due to atypical microorganisms doesn't seem to be a frequent condition in inpatients with diagnosis of community-acquired pneumonia. Research in larger populations, including outpatients should be done, in order to define the role of atypical pathogens in cases of pneumonia at a national level.
RESUMO
Pneumonia is an infectious disease caused by bacteria, viruses or fungi that results in millions of deaths globally. Despite the existence of prophylactic methods against some of the major pathogens of the disease, there is no efficient prophylaxis against atypical agents such as Mycoplasma pneumoniae, a bacterium associated with cases of community-acquired pneumonia. Because of the morphological peculiarity of M. pneumoniae, which leads to an increased resistance to antibiotics, studies that prospectively investigate the development of vaccines and drug targets appear to be one of the best ways forward. Hence, in this paper, bioinformatics tools were used for vaccine and pharmacological prediction. We conducted comparative genomic analysis on the genomes of 88 M. pneumoniae strains, as opposed to a reverse vaccinology analysis, in relation to the capacity of M. pneumoniae proteins to bind to the major histocompatibility complex, revealing seven targets with immunogenic potential. Predictive cytoplasmic proteins were tested as potential drug targets by studying their structures in relation to other proteins, metabolic pathways and molecular anchorage, which identified five possible drug targets. These findings are a valuable addition to the development of vaccines and the selection of new in vivo drug targets that may contribute to further elucidating the molecular basis of M. pneumoniae-host interactions.
RESUMO
Se presenta el caso de un niño de 5 años sin antecedentes de enfermedad, que se internó en terapia intensiva por convulsiones tónico-clónicas focalizadas en la cara y en el hemicuerpo derecho, con documentación de temperatura axilar de 37,4°C. Se descartó la presencia de gérmenes comunes y la etiología viral a través de estudios de muestras de líquido cefalorraquídeo (LCR). Se sospechó la presencia de Mycoplasma pneumoniae por comprobarse inmunofluorescencia positiva en suero para anticuerpos de clase IgM. El diagnóstico se confirmó mediante la detección del ADN de dicho patógeno sobre la biopsia cerebral efectuada por el método de la reacción en cadena de la polimerasa (PCR) y una histología compatible con encefalomielitis aguda diseminada. El paciente recibió tratamiento con claritromicina y su evolución fue favorable. Al menos dentro de nuestros conocimientos, este es el primer caso en el que se detectó ADN de M. pneumoniae en una biopsia cerebral por el método de PCR.
We present here the case of a previously healthy 5 year-old boy hospitalized in an intensive care unit due to tonic-clonic seizures focused on the face and right side of the body, and axillary temperature of 37.4 °C. Common bacterial and viral etiology was ruled out through studies of cerebrospinal fluid (CSF) samples. Mycoplasma pneumoniae was suspected by a positive immunofluorescence serum test for IgM class antibodies. Finally, with a brain biopsy, M. pneumoniae was confirmed by polymerase chain reaction (PCR) and acute disseminated encephalomyelitis by pathological anatomy. The patient was treated with clarithromycin and had an uneventful evolution. At least to our knowledge, this is the first case in which M. pneumoniae DNA was detected by PCR in a brain biopsy.